Effects of L-dopa, GPA 1734 and other agents on basement membrane biosynthesis.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D001485:Basement Membrane / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D003094:Collagen / Q000096:biosynthesis*; D003920:Diabetes Mellitus / Q000378:metabolism; D005260:Female; D006728:Hormones / Q000494:pharmacology; D066298:In Vitro Techniques; D007980:Levodopa / Q000494:pharmacology*; D008870:Microtubules / Q000187:drug effects; D011247:Pregnancy; D011393:Procollagen-Proline Dioxygenase / Q000037:antagonists & inhibitors; D011453:Prostaglandins / Q000494:pharmacology; D011807:Quinolizines / Q000494:pharmacology*; D051381:Rats; D012867:Skin / Q000201:enzymology
D006728:Hormones; D011453:Prostaglandins; D011807:Quinolizines; C015607:GPA 1734; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D007980:Levodopa; D003094:Collagen; D011393:Procollagen-Proline Dioxygenase